association between macrophage migration inhibitory factor promoter region polymorphism (-173 gc) and cancer a meta-analysis巨噬细胞迁移抑制因子启动子区域之间的联系分析多态性(-173 gc)和癌症.pdfVIP

Vera and Meyer-Siegler BMC Research Notes 2011, 4:395 /1756-0500/4/395 RESEARCH ARTICLE Open Access Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis Pedro L Vera1,2* and Katherine L Meyer-Siegler1,3 Abstract Background: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine upstream of many inflammatory cytokines. MIF is implicated in several acute and chronic inflammatory conditions. MIF’s promoter region has functional single nucleotide polymorphisms that controls MIF expression and protein levels. Since increased plasma MIF levels are associated with cancer, studies have examined the association between Mif promoter polymorphisms and cancer. This study is a meta-analysis of the available studies on such an association. Results: A total of 5 studies were included in this meta-analysis to include 1116 cases (cancer patients) and 1728 controls (no cancer). Carrying any C allele in the Mif -173 G/C promoter polymorphism resulted in a significantly greater risk for developing cancer [OR = 1.89 (1.15-3.11), p = 0.012)] when compared to the (G/G) genotype. Subgroup analysis revealed that this association was significant only for “solid” tumors (including gastric and prostate cancers) [OR = 2.67 (1.26-5.65), p = 0.010] but not for “non-solid” tumors (leukemia) [OR = 1.21 (0.95-1.55), p = 0.122]. Furthermore, when only prostate tumor studies were included in the analysis, the association became even stronger [OR = 3.72 (2.55-5.41), p 0.0001]. Conclusions: Meta-analysis suggests there is an association between any C allele in the Mif -173 G/C promoter polymorphism and an increased risk of cancer, particularly for solid tumors. The association appeared stronger for prostate cancer, specifically. Future studies that inclu